Related Experiment Video
Updated: Jun 30, 2025
03:26
Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
2.6K
Mesenchymal Stem Cell Engagement Modulates Neuroma Microenviroment in Rats and Humans and Prevents Postamputation
Mailín Casadei1, Bernardo Miguel1, Julia Rubione1
1Laboratorio de Mecanismos e Innovación Terapéutico en Dolor, Instituto de Investigaciones en Medicina Traslacional, CONICET-Universidad Austral, Buenos Aires, Argentina.
The Journal of Pain
|March 14, 2024
Summary
Mesenchymal stem cells (MSCs) show promise for treating postamputation pain by reducing inflammation. The compound IMT504 effectively engages MSCs to prevent pain behaviors in animal models, offering a new therapeutic avenue.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Pain Research
Background:
- Postamputation pain remains difficult to manage with current therapies targeting neurons.
- Non-neuronal mechanisms are increasingly recognized as critical in the development and persistence of this pain.
- Mesenchymal stem cells (MSCs) present a potential therapeutic target for modulating neuroinflammation.
Purpose of the Study:
- To investigate if engaging mesenchymal stem cells (MSCs) can reduce postamputation pain.
- To explore the role of the oligodeoxynucleotide IMT504 in modulating MSCs and neuroinflammation.
- To assess the therapeutic potential of IMT504 in preclinical models of postamputation pain.
Main Methods:
- Utilized an ex vivo neuroma model from a phantom limb pain patient.
- Investigated the effect of IMT504 on human primary MSCs and the resulting microenvironment.
- Conducted reverse translation experiments in an in vivo rat model of autotomy.
- Analyzed MSC accumulation, anti-inflammatory phenotype, and glial reactivity in the spinal cord.
Main Results:
- IMT504 engaged MSCs to promote an anti-inflammatory microenvironment in vitro.
- IMT504 significantly reduced autotomy behaviors in a rat model.
- MSC accumulation and an anti-inflammatory phenotype were observed in neuromas and dorsal root ganglia.
- Central glial reactivity was reduced, indicating diminished nociceptive activity.
Conclusions:
- Engaging endogenous mesenchymal stem cells (MSCs) via IMT504 can prevent postamputation pain by modulating the inflammatory environment.
- IMT504 demonstrates significant therapeutic potential for preventing postamputation pain by targeting non-neuronal mechanisms.
- Findings support the clinical value of IMT504 for patients experiencing postamputation pain.
